IPO13

Across TCGA pan-cancer cohorts, IPO13 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated IPO13 data layer compared with 21 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher IPO13 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated IPO13 expression acts as an unfavorable survival marker.

LUSC, LIHC, and LGG are the cancer types where IPO13 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	DFS	Median	All	0.079	0.792	<.001	24	view →
LIHC	DFS	Median	All	0.081	0.527	.012	12	view →
LGG	OS	Median	All	0.238	0.799	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

IPO13–LUSC (DFS)

Open the LUSC breakdown →